Home Business AstraZeneca Pauses £200m Cambridge Expansion as UK Pharma Future in Doubt
BusinessNews

AstraZeneca Pauses £200m Cambridge Expansion as UK Pharma Future in Doubt

Global pressures and waning government support threaten Britain’s life sciences hub.

Share
astrazeneca-disc-cambridge
CND
Share

Cambridge’s reputation as a world-class hub for life sciences suffered a setback on Friday after AstraZeneca paused a £200m expansion at its Discovery Centre. The project, first announced in March 2024, promised to create 1,000 jobs and strengthen Britain’s pharmaceutical industry.

The decision is the second major retreat from the UK by the firm this year, following its withdrawal from a planned £450m vaccine facility in Liverpool. It also mirrors moves by rivals such as Merck, which recently abandoned a £1bn research site in London.

An AstraZeneca spokesperson confirmed: “We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused.”

Industry leaders warn the shift reflects broader pressures. Over the past decade, UK spending on medicines has declined from 15% of the NHS budget to just 9%. In contrast, other developed nations invest between 14% and 20%. Many global pharmaceutical firms are now turning to the United States, where President Donald Trump has pushed aggressively for domestic investment and threatened tariffs on imports.

In July, AstraZeneca chief executive Pascal Soriot unveiled a $50bn (£36.9bn) US investment plan for research and manufacturing. Days later, Merck revealed it would abandon its nearly complete King’s Cross site, shifting operations to the US and cutting British jobs.

The shelved Cambridge project would have expanded AstraZeneca’s existing Discovery Centre, already home to 2,300 scientists. Its suspension leaves none of the £650m in life sciences investments announced by the previous UK government currently moving forward.

Successive governments have hailed pharmaceuticals as a cornerstone of Britain’s economy. Former chancellor Jeremy Hunt called the sector “crucial for the country’s health, wealth and resilience”, while his successor Rachel Reeves praised AstraZeneca as one of the nation’s “great companies” only days before the Liverpool project was scrapped.

Analysts warn that without a stronger partnership between government and industry, the UK risks losing its position as a global leader in research and development. For Cambridge, a city that has long been at the heart of scientific innovation, the pause signals a sobering reminder of how international competition and domestic policy collide.

Share

Don't Miss

Council Failed to Manage Cambridgeshire Busway Risk

Cambridgeshire County Council has admitted to failing in its duty to manage safety risks on the guided busway that serves Cambridge, Huntingdon, and...

Luminance Reflects on Five Years Transforming the Legal Industry

In just five years, Luminance has evolved from an ambitious AI concept in Cambridge to a global leader in legal technology, boasting over...

Baby Bust in Rural Cambridgeshire

In the heart of Cambridgeshire, from the market town of St Neots to the rural fringes of Huntingdonshire, a silent shift is underway....

Related Articles

New Cambridge East Railway Station Proposed

A fresh proposal for a new railway station in East Cambridge has...

North London Man Fined £9,000 After Waste Dumped in South Cambridgeshire

A North London resident has been left with a criminal record and...

Ambitious ‘Forest City 1’ Plan Near Cambridge Unveiled

Plans for a vast new city capable of housing one million people...

Closure Order Issued on Cambridge Home After Surge in Anti-Social Behaviour

A Cambridge home at the centre of repeated complaints about anti-social behaviour...